Pluristem Placental Cells Found Effective For Several Treatments
August 30, 2010 · Filed Under stem cells
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) is up 12.87% this morning after it announced that its PLX therapeutic stem cell line, derived from the material of a human placenta, would be the only type of cell selected for a study designed to prevent inflammatory heart disease, also called diastolic heart failure.
Shares of PSTI is up $0.13 to $1.14 on 172 thousand shares of volume, more than three times the average daily volume of 48,248 shares. the stock is mid-way through its 52-week range of $0.82 to $1.52.
-Michael B. Sauter
Comments
Leave a Reply
